Loading financial data...

DYADIC INTERNATIONAL INC

DYAISEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1213809

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$2.9M	$2.9M	$2.4M	$1.6M	$1.7M
Cost of Goods and Services Sold	$2.0M	$2.1M	$1.9M	$1.4M	$1.5M
Research and Development Expense	$3.3M	$4.5M	$8.4M	$3.9M	$3.1M
Operating Income (Loss)	-$8.2M	-$10.2M	-$14.7M	-$10.0M	-$9.3M
Nonoperating Income (Expense)	$1.4M	$430.4K	$1.7M	$731.7K	—
Income Tax Expense (Benefit)	—	—	—	$31.3K	$10.3K
Net Income (Loss) Attributable to Parent	-$6.8M	-$9.7M	-$13.1M	-$9.3M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$8.2M	$13.7M	$21.3M	$30.1M	$37.5M
Assets, Current	$8.1M	$13.4M	$21.0M	$29.8M	$35.6M
Cash and Cash Equivalents, at Carrying Value	$6.5M	$5.8M	$15.7M	$20.6M	$4.8M
Accounts Receivable, after Allowance for Credit Loss, Current	$466.2K	$330.0K	$277.8K	$294.2K	$558.5K
Liabilities	$2.3M	$2.6M	$2.9M	$1.6M	—
Liabilities, Current	$2.3M	$2.4M	$2.6M	$1.6M	$1.6M
Accounts Payable, Current	$656.4K	$1.3M	$1.5M	$1.0M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$6.7M	-$8.1M	-$11.3M	-$6.6M	-$5.8M
Net Cash Provided by (Used in) Investing Activities	$7.4M	-$2.4M	$5.2M	$22.1M	$7.7M
Net Cash Provided by (Used in) Financing Activities	$0.00	$543.6K	$1.2M	$255.5K	$550.2K
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)

DYADIC INTERNATIONAL INC (DYAI) Financial Statements | Global Financial Data